is semaglutide fda approved for mash Approval Expands Novo Nordisk's Wegovy to the Fatty Liver Disease GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT

do not share your pen

The STEP 1 obesity trial gives a sense of the scale of the effect: The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, for an estimated treatment difference of -12.4 percentage points (95% confidence interval [CI], -13.4 to -11.5

Plus, get exercises and tips from Hinge Health physical therapists

Additionally, dosing errors with compounded products can cause more severe symptoms than would occur with properly dosed medication

Patients should be instructed on the importance of rotating injection sites, monitoring blood glucose levels if applicable, and seeking medical attention if they experience any concerning symptoms or adverse reactions

Bioact Mater 36:203220